Business
Join Cannabics Pharmaceuticals at the MJBizCon Held at Metro Toronto Convention Center, Toronto, August 14-16, 2018
Join Cannabics Pharmaceuticals at the MJBizCon Held at Metro Toronto Convention Center, Toronto, August 14-16, 2018.
About this update from Cnbx Pharmaceuticals Inc.
[{"type":"text","content":"\n\n\n\nJoin Cannabics Pharmaceuticals at the MJBizCon Held at Metro Toronto Convention Center, Toronto, August 14-16, 2018\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nJoin Cannabics Pharmaceuticals at the MJBizCon Held at Metro Toronto Convention Center, Toronto, August 14-16, 2018\nPR Newswire\nTEL AVIV, Israel and BETHESDA, Maryland, August 9, 2018\n\n\n\nTEL AVIV, Israel and BETHESDA, Maryland, August 9, 2018 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that its CEO, Mr. Eyal Barad, will be attending the MJBizCon Conference and Expo, to be held in the Toronto Metro Convention Centre, on August 14th-16th  2018, and will be available for one-on-one meetings.\n\n\nThe MJBizCon, held three times a year, is the largest event of its kind. The event brings together over 2,000 leaders from around the globe focusing on the role of the cannabis global marketplace in the industry today.\n\nEyal Barad, CEO of the company, said: \"We are excited to be able to meet and network with fellow companies in the Cannabis sector. We see collaboration and cooperation with partners as a cornerstone to realizing our vision moving forward, which is to introduce cannabinoids into modern, precision medicine.\"\n\nMr. Barad will be accepting one-on-one meetings. Please email [email protected]\n\nAbout Cannabics Pharmaceuticals  Cannabics Pharmaceuticals Inc. (CNBX) is a United States-based public company that is developing cannabinoid diagnostic tests for the personalized treatment of cancer. Cannabics is developing a blood test that allows practitioners to precisely tailor medical cannabinoid-based therapies to an individual patient's profile and cancer. Cannabics' approach can also be used to develop cannabinoid-based therapies as preventive or primary cancer treatments – not just palliative, the way it's being used now. By developing tools to assess effectiveness on a personalized basis, Cannabics is helping to move...